Long non‐coding NR2F1‐AS1 is associated with tumor recurrence in estrogen receptor‐positive breast cancers

The tenacity of late recurrence of estrogen receptor (ER)‐positive breast cancer remains a major clinical issue to overcome. The administration of endocrine therapies within the first 5 years substantially minimizes the risk of relapse; however, some tumors reappear 10–20 years after the initial dia...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanchez Calle, Anna, Yamamoto, Tomofumi, Kawamura, Yumi, Hironaka‐Mitsuhashi, Ai, Ono, Makiko, Tsuda, Hitoshi, Shimomura, Akihiko, Tamura, Kenji, Takeshita, Fumitaka, Ochiya, Takahiro, Yamamoto, Yusuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463365/
https://www.ncbi.nlm.nih.gov/pubmed/32392629
http://dx.doi.org/10.1002/1878-0261.12704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463365/
https://www.ncbi.nlm.nih.gov/pubmed/32392629
http://dx.doi.org/10.1002/1878-0261.12704

Ejemplares similares